诊断后时间与死亡率对癌症相关静脉血栓栓塞症的影响:斯堪的纳维亚血栓与癌症(STAC)队列研究
该队列纳入144 952名参与者,随访期间14 272人发生癌症、567人发生癌症相关静脉血栓栓塞症(VTE)。按死因竞争风险分析时,VTE风险在癌症诊断后前6个月最高(HR 17.5,95%CI 15.1-20.3),随后迅速下降;考虑死亡竞争风险后,诊断前6个月(SHR 4.8,95%CI 3.6-6.4)与诊断后6个月(SHR 4.6,95%CI 3.9-5.4)风险相似。考虑死亡竞争风险后,各癌种2年累积VTE发生率范围由1-10%收窄至1-4%。
要点
- 死因竞争风险可导致高死亡率癌症的VTE风险被高估。
- 按死因竞争风险分析,诊断前后6个月VTE风险相似(SHR 4.8 vs 4.6)。
- 考虑死亡竞争风险后,各癌种2年累积VTE发生率范围由1-10%收窄至1-4%。
核心结论
- 各癌种的VTE风险受死亡率和癌症诊断后时间影响。
- 作者认为癌症本身是VTE风险的主要贡献因素。
- 作者认为在探讨癌症VTE风险时应考虑死因竞争风险。
研究设计与样本
- 斯堪的纳维亚血栓与癌症(STAC)队列纳入144 952名参与者,随访自1993-1997年至2008-2012年。
- 评估总体癌症及各癌种的发病率、病因特异性风险比(HR)和亚分布风险比(SHR),并按癌症诊断后时间区间分析。
主要发现
- 随访期间14 272人发生癌症,567人发生癌症相关VTE。
- 病因特异性分析中,VTE风险在癌症诊断后前6个月最高(HR 17.5,95%CI 15.1-20.3),随后迅速下降。
- 考虑死亡竞争风险后,诊断前6个月(SHR 4.8,95%CI 3.6-6.4)与诊断后6个月(SHR 4.6,95%CI 3.9-5.4)VTE风险相似。
- 考虑死亡竞争风险后,各癌种2年累积VTE发生率范围由1-10%收窄至1-4%。
关键数值与推荐
- 癌症诊断后前6个月VTE的病因特异性HR为17.5(95%CI 15.1-20.3)。
- 诊断前6个月VTE的SHR为4.8(95%CI 3.6-6.4),诊断后6个月SHR为4.6(95%CI 3.9-5.4)。
- 考虑死亡竞争风险后,各癌种2年累积VTE发生率范围由1-10%收窄至1-4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Competing risk by death may lead to overestimation of venous thromboembolism (VTE) risk in cancers. We assessed the risk of VTE in cancer with and without accounting for competing risk by death. The risk of VTE was influenced by the mortality rate and the time since cancer diagnosis. Competing risk by death should be taken into account when exploring VTE risk in cancer. SUMMARY: Background Venous thromboembolism (VTE) is a common complication in cancer, and studies have suggested that aggressive cancers create the highest risk of VTE. However, competing risk by death may result in overestimation of VTE risk in patients with cancers associated with high mortality. Therefore, we estimated the risk of VTE by cancer site, accounting for the differential mortality between cancers. Methods The Scandinavian Thrombosis and Cancer cohort included 144 952 participants followed from 1993-1997 to 2008-2012. Incidence rates, cause-specific hazard ratios (HRs) and subdistribution HRs (SHRs) were assessed for overall cancer and by cancer site according to time intervals since cancer diagnosis. Results During follow-up, 14 272 subjects developed cancer, and 567 had cancer-related VTE. In cause-specific analyses, the VTE risk was highest in the first 6 months after cancer diagnosis (HR 17.5, 95% confidence interval [CI] 15.1-20.3), and declined rapidly thereafter. However, when mortality was taken into account, the risk was similar in the periods 6 months before (SHR 4.8, 95% CI 3.6-6.4) and 6 months after (SHR 4.6, 95% CI 3.9-5.4) cancer diagnosis. The range of the 2-year cumulative VTE incidence rates was substantially narrowed for all cancer sites after competing risk by death was taken into account (from 1-10% to 1-4%). Conclusion VTE risk by cancer site was influenced by the mortality rate and the time since cancer diagnosis. Our findings suggest that the cancer itself is a major contributor to VTE risk, and that competing risk by death should be taken into account when VTE risk in cancer is explored.
引用
- Blix K, Gran OV, Severinsen MT, et al. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. J Thromb Haemost. 2018. PMID: 29691978. doi:10.1111/jth.14130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。